Supercharge Your Innovation With Domain-Expert AI Agents!

A kind of anti-tumor combination drug and its application in the preparation of anti-cancer drug

An anti-tumor and drug technology, applied in the field of biomedicine

Active Publication Date: 2020-11-06
SICHUAN JIUZHANG BIO TECH CO LTD
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The technical solution of the present application can solve the defects of drug resistance and various toxic and side effects of VEGF tyrosine kinase inhibitors due to long-term use or frequent use, improve the targeting of VEGF pathway inhibitors, reduce toxic and side effects, and improve patient compliance

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A kind of anti-tumor combination drug and its application in the preparation of anti-cancer drug
  • A kind of anti-tumor combination drug and its application in the preparation of anti-cancer drug
  • A kind of anti-tumor combination drug and its application in the preparation of anti-cancer drug

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0034] Example 1 MTT Determination of Proliferation Inhibition of Combination Drugs

[0035] 1.1 Materials and Instruments

[0036] Test drugs: chlorogenic acid, sorafenib, sunitinib, axitinib, pazopanib, bevacizumab.

[0037] Tested cell lines: human lung cancer cell line A549, human kidney cancer cell line 786-0, human normal lung epithelial cell BEAS-2B, human embryonic kidney normal cell CCC-HEK-1

[0038] 1.2 Experimental method

[0039] One bottle of tumor cells in the logarithmic growth phase was taken, washed twice with PBS, digested with 0.25% trypsin, and prepared into a single cell suspension with RPMI-1640 culture medium containing 10% calf serum for counting. Inoculate 100 μl of cells in a 96-well culture plate under sterile conditions, and the number of inoculated cells is 5xl0 3 / hole. cells at 37°C, 5% CO 2 After incubation for 24 h in the incubator, the medium was replaced.

[0040] Cells were divided into negative control group, single drug group, chlor...

Embodiment 2

[0061] Anti-tumor animal test of embodiment 2 combined drug

[0062] 2.1 Materials and methods

[0063] Test drug: chlorogenic acid; VEGFR tyrosine kinase inhibitors: sorafenib, sunitinib, axitinib, pazopanib, bevacizumab

[0064] Tested cell lines: lung cancer cell line A549 cells, human renal cancer cell line 786-0

[0065] Test animals: BABL / C-nu mice, ♀, weighing 18-22g;

[0066] 2.2 Test method

[0067] 2.2.1 Establishment of experimental animal tumor models

[0068] Collect the cells in the logarithmic growth phase, centrifuge at 1000rpm for 5min, wash the cell sediment twice with PBS, and adjust the cell concentration to 1x10 with serum-free medium after counting 7 / m1, sent to the animal room under sterile conditions. Under sterile experimental conditions, mice were subcutaneously injected with 1x10 7 / m1 cells, 0.1ml per mouse, obvious skin mounds appeared in the injection site, and a large rice grain nodule appeared in the left armpit of the mouse after 1 week,...

Embodiment 3

[0104] Embodiment 3 Chlorogenic acid is in the animal experiment of preparation anti-multidrug resistance combination medicine

[0105] 3.1 Materials and methods

[0106] Test drugs: chlorogenic acid; VEGF tyrosine kinase inhibitors: sorafenib, pazopanib.

[0107] Tested cell line: lung cancer drug-resistant cell line A549, the A549 cell line was induced by sorafenib concentration gradient method, and established by clonal screening, drug-free culture before the experiment.

[0108] The human kidney cancer drug-resistant cell line 786-0 was induced by the method of increasing the concentration gradient of pazotinib to the A549 cell line, and was established by clonal screening, and cultured without drug before the experiment.

[0109] Test animals: BABL / C-nu mice, ♀, weighing 18-22g;

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an anti-tumor combined drug and use thereof in preparing an anti-cancer drug. The combined drug comprises 10-40 weight parts of a first preparation and 2-100 weight parts of a second preparation. The invention further discloses use of chlorogenic acid in preparing an anti-cancer drug toxic and side effect inhibitor, and the anti-cancer drug is a VEGF channel inhibitor. According to the technical scheme adopted by the invention, targeting ability, to lung cancer and kidney cancer, of the VEGF channel inhibitor can be improved, and the toxic and side effect of the VEGF channel inhibitor can be reduced; and moreover, drug resistance of a VEGF tyrosine kinase inhibitor further can be reversed.

Description

technical field [0001] The invention relates to the field of biomedicine, in particular to an anti-tumor combined drug and its use in the preparation of anti-cancer drugs. Background technique [0002] Chlorogenic acid is a carboxyphenolic acid composed of caffeic acid and quinic acid. The structural formula is as follows [0003] [0004] Chlorogenic acid has a wide range of pharmacological effects, including biological activities such as anti-oxidation, anti-bacterial and anti-inflammatory, tumor inhibition, liver protection and gallbladder, blood circulation and blood pressure reduction. [0005] Tumor is one of the major diseases that endanger human health today and seriously threatens human life. Most human tumors are solid tumors. Angiogenesis is a necessary condition for the growth and metastasis of solid tumor cells. Angiogenesis can provide tumor cells with more Therefore, preventing the formation of tumor vascular network can make tumors smaller and prevent tu...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/216A61K45/06A61K31/44A61K31/404A61K31/4439A61K31/506A61P35/00
CPCA61K31/216A61K31/404A61K31/44A61K31/4439A61K31/506A61K45/06A61K2300/00
Inventor 张洁黄望杨华蓉张梦甜
Owner SICHUAN JIUZHANG BIO TECH CO LTD
Features
  • R&D
  • Intellectual Property
  • Life Sciences
  • Materials
  • Tech Scout
Why Patsnap Eureka
  • Unparalleled Data Quality
  • Higher Quality Content
  • 60% Fewer Hallucinations
Social media
Patsnap Eureka Blog
Learn More

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2025 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com